The Life Sciences Division's Dr Navid Malik offers up his thoughts and outlook on () and its flagship drug Lupuzor - a treatment for the autoimmune disease Lupus.
Dr Malik says despite not meeting its primary end point in a recent phase III trial, the response rate overall compares well to a number of other pivotal studies and has an excellent safety profile.
Worldwide, there are 5mln people with Lupus, 1.5mln of them in the US, Europe and Japan.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of ImmuPharma PLC named herein, including the promotion by the Company of ImmuPharma PLC in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE